The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Allogene Therapeutics, Inc. | Common Stock | 019770106 | 67,809 | 1,798,163 | SH | SOLE | 1,798,163 | 0 | 0 | ||
| Assembly Biosciences, Inc. | Common Stock | 045396108 | 7,398 | 450,000 | SH | SOLE | 450,000 | 0 | 0 | ||
| Dyne Therapeutics, Inc. | Common Stock | 26818M108 | 59,764 | 2,960,046 | SH | SOLE | 2,960,046 | 0 | 0 | ||
| Homology Medicines, Inc. | Common Stock | 438083107 | 8,248 | 770,845 | SH | SOLE | 770,845 | 0 | 0 | ||
| Oyster Pt Pharma Inc | Common Stock | 69242L106 | 16,433 | 778,468 | SH | SOLE | 778,468 | 0 | 0 | ||